|
시장보고서
Solvay
Pipeline * Products * Performance * Potential
|
Abstract
Pharmaceutical company intelligence reports from Espicom provide a full review
of the company' s activities together with five-year sales forecasts for its
key products. The company' s financial performance is covered in-depth, from
its latest results to a complete analysis of its latest full fiscal year and
an outlook for the future. A section on company strategy covers mergers,
acquisitions and divestitures, key agreements, products and R&D. An overview
of key products and R&D is followed by a comprehensive review of the company' s
product portfolio and research and development pipeline by therapeutic area.
In addition, supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company
strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- CardioMetabolic Care
- Physiotens/Cynt (moxonidine)
- Teveten (eprosartan mesylate)
- TriCor/Lipanthyl (fenofibrate)
- Women' s and Men' s Health
- AndroGel/Andractim (dihydro testosterone)
- Estratest (esterified oestrogens)
- Neuroscience
- Duodopa (levodopa+carbidopa)
- Luvox (fluvoxamine)
- Marinol (dronabinol)
- Serc/Betaserc (betahistine)
- Gastroenterology
- Duphalac (laxative lactulose)
- Pancreatic Enzymes
- Creon (porcine pancreatin supplement)
- Influenza Vaccines
- Influvac (inactivated influenza surface antigen)
- Invivac
OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
|
